| | | 塞力斯医疗科技集团股份有限公司 关于为控股子公司提供担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 被担保人名称 | | 塞力斯（上海）医疗科技有限公司 | | --- | --- | --- | --- | --- | | | | 本次担保金额 | 5,000 万元 | | | 担 保 象一 | 对 | 实际为其提供的担保余额 | 0 万元 | | | | | 是否在前期预计额度内 | □是 □否 | ☑不适用：新增预计额度 | | | | 本次担保是否有反担保 | □是 ☑否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 | | 武汉塞力斯生物技术有限公司 | | | | 本次担保金额 | 2,000 万元 | | | 象二 | | 实际为其提供的担保余额 | 0 万元 | | | | | 是否在前期预计额度内 | □是 □否 | ☑不适用：新增预计额度 | | | | 本次担保是否有反担保 | □是 ☑否 | □ ...

第五届董事会第二十三次会议决议公告 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-096 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 （一）审议通过《关于不提前赎回"塞力转债"的议案》 自 2025 年 10 月 22 日至 2025 年 11 月 11 日收盘，公司股票已有十五个交易 日的收盘价不低于"塞力转债"当期转股价格的 130%（即 15.60 元/股），已触 发"塞力转债"的有条件赎回条款。 全体董事均亲自出席本次董事会； 无董事对本次董事会议案投反对/弃权票； 本次董事会全部议案已获通过。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日在公司 A 栋 C 会议室以现场和通讯相结合的方式临时召开第五届董事会第 二十三次会议。经全体董事一致同意，本次会议豁免通知时限要求。 ...

Group 1 - The core point of the article is that Sely Medical (SH 603716) held a temporary board meeting on November 11, 2025, to discuss the proposal for providing guarantee limits for its subsidiary [1] - For the fiscal year 2024, Sely Medical's revenue composition is 97.09% from commercial activities and 2.91% from industrial activities [1] - As of the report date, Sely Medical has a market capitalization of 4.9 billion yuan [1] Group 2 - Prior to the arrest of Peking University Pharmaceutical's chairman Xu Xiren, police had investigated the group's factory premises, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by Xu, with significant amounts of funds unaccounted for [1]

Core Insights - The pharmaceutical commercial sector experienced a decline of 0.52% on November 6, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - The top-performing stock was HeFu China (603122), which closed at 14.34, up 9.97% with a trading volume of 1.2541 million shares and a transaction value of 1.757 billion [1] - Other notable gainers included Yinghe Shiyao (002788) at 9.33, up 5.19%, and Yingche Dong (002462) at 14.68, up 1.45% [1] - Conversely, Renmin Tongtai (600829) saw a significant drop of 9.98%, closing at 65.6 with a trading volume of 521,700 shares and a transaction value of 500 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 467 million from institutional investors, while retail investors saw a net inflow of 408 million [2] - The overall capital flow indicates that while institutional investors withdrew funds, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Notable net inflows from retail investors were observed in stocks like Yifeng Pharmacy (603939) with a retail net inflow of 412.67 million, while institutional investors had a net inflow of 287.47 million in Nanjing Pharmaceutical (600713) [3] - Conversely, stocks like Luyuan Pharmaceutical (002788) and Jia Shitang (002462) experienced net outflows from both institutional and retail investors [3]

Core Viewpoint - The article highlights that Seer Medical's strategic subsidiary, Huajiyuan Bio, has initiated a Phase I clinical trial for an innovative drug, HJY-ATRQβ-001 injection, which is a therapeutic vaccine for hypertension targeting the angiotensin II receptor type I. This marks a significant step as it has received ethical approval from the Ethics Committee of Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital [1]. Group 1 - Seer Medical's strategic investment in Huajiyuan Bio has led to the development of HJY-ATRQβ-001, an innovative therapeutic vaccine for hypertension [1]. - The Phase I clinical trial is being conducted in collaboration with Standeam (Beijing) Pharmaceutical as the CRO [1]. - The ethical approval from the relevant medical ethics committee signifies a crucial milestone in the drug's journey towards human clinical trials [1].

Group 1 - The core viewpoint of the news is that Sely Medical has seen a stock price increase of 5.89%, reaching 26.24 CNY per share, with a total market capitalization of 5.515 billion CNY [1] - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, specializes in medical testing services, in vitro diagnostic product agency, and the research, production, and sales of its own in vitro diagnostic products [1] - The revenue composition of Sely Medical includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under GF Fund ranks among the top shareholders of Sely Medical, with GF Healthcare Stock A (004851) newly entering the top ten in Q3, holding 1.2236 million shares, which is 0.58% of the circulating shares [2] - The estimated floating profit for GF Healthcare Stock A today is approximately 1.7864 million CNY [2] - GF Healthcare Stock A was established on August 10, 2017, with a latest scale of 5.185 billion CNY, and has achieved a year-to-date return of 19.74%, ranking 2756 out of 4216 in its category [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券发行上市概况 （一）可转换公司债券发行情况 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"预计满足赎回条件的提示性公告 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 54,331万元的可转换公司债券于2020年9月15日起在上海证券交易所挂牌交易， 债券简称"塞力转债"，债券代码"11 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-095 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 14 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 11 月 14 日 前 访 问 网 址 https://eseb.cn/1sNcORnvdqE 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 公 司 定 于 2025 年 11 月 14 日 （ 星 期 五 ） 10:00-11:00 在 " 价 值 在 线 " （www.ir-online.cn）举办塞力斯医疗科技集团股份有限公司 2025 年第三季度 业绩说明会，与 ...

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Insights - The pharmaceutical commercial sector experienced a rise of 0.69% on November 3, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - HeFu China (603122) closed at 10.77, with a significant increase of 10.01% and a trading volume of 252,300 shares, amounting to a transaction value of 271 million [1] - Jianfa Zhixin (301584) saw a rise of 3.98%, closing at 33.67 with a trading volume of 143,300 shares [1] - Renmin Tongtai (600829) increased by 3.93%, closing at 8.99 with a trading volume of 337,500 shares [1] - Other notable performers include Jia Shitang (002462) with a 2.43% increase and Sai Li Medical (603716) with a 2.36% increase [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 78.21 million from institutional investors, while retail investors saw a net inflow of 94.46 million [2] - The top stocks by net inflow from retail investors include Renmin Tongtai (600829) with 17.00 million and Baiyang Pharmaceutical (301015) with 16.33 million [3] - Conversely, institutional investors showed a significant net inflow in Guoyao Yizhi (000028) with 15.04 million, indicating strong institutional interest [3]